Treprostinil Injection, Teglutik® and Trittico®, the commercialized products of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) have been included for the first time into the updated National Reimbursement Drug List (the “NRDL”) issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group’s Treprostinil Injection and Teglutik® have taken up 2 places thereof. Lee’s Pharm firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordability and accessibility thereof among patients in rare disease and mental health areas.

Hong Kong, December 22, 2022, the “STEM Experience Program for Secondary Students——Kanya Lee Scholarship Recognition Ceremony 2022” was successfully held in Hyatt Regency Hong Kong, Tsim Sha Tsui. Established in 2021, the Kanya Lee Scholarship Program, co-organized with Caritas School Social Work Service, aims at providing support to the secondary students with economic burden to fully develop their potentials and talents, as well as to explore the future. Apart from the one-off scholarship and monthly subsidy, the Group provides practical internship opportunities for students who are interested in scientific and research field. To date, a total of 59 secondary school students have been benefited from this scholarship program.

Hong Kong, December 14-17, 2022, the International Convention for Biotechnology in Hong Kong 2022 (BIOHK2022), co-organized by the Hong Kong Biotechnology Organization, BayHelix Group and Ausvic Capital was successfully held in the Hong Kong Convention and Exhibition Centre. As the first international biotech exhibition organized in Hong Kong, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), the Diamond Sponsor, actively participated in the BIOHK2022, which intends to drive Hong Kong biotechnology development, enhance international business connections and create investment opportunities.

Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the HKMVC 2022 award with the title of “Most Innovative Pharmaceutical Company”, in recognition of its extensive research and development experience and solid infrastructures. Dr. LI Xiaoyi Benjamin, the Founder and Director of Lee’s Pharm was invited to attend the ceremony and receive the award. Interview session was featured in the ceremony, giving insight into the achievements and latest development of winning companies. According to Dr. Li, Lee’s Pharm has launched various products in this year, such as the in-licensed products, Teglutik® and INOmax®, which help patients suffering from rare disease. To date, the Group has more than 40 products in its pipeline from early- to late-stage development. More products are expected to be launched in 2023, such as an oncology product treating cervical cancer. Lee’s Pharm focuses on China, Hong Kong and Taiwan market, and is expanding its business to Southeast Asia in 2023 by providing innovative pharmaceutical products, especially in the field of rare disease. Please click on the video below to watch the full interview.

State Council announced the “General Plan of Nansha, Guangzhou for Deepening Globally Oriented Comprehensive Co-operation amongst Guangdong, Hong Kong and Macau” (Nansha Plan) in June 2022 and implemented taxation rate adjustment in Nansha recently. Dr. LI Xiaoyi, the Founder and Director of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was interviewed by Southern Finance Omnimedia Group about the benefits of Nansha Plan that illustrate the development in pharmaceutical industry and advancement of technology.

The rare disease community has received increased public attention as Chinese authorities has issued a circular on further promoting the prevention and control measures, while strengthening the supportive care needs of patients with rare diseases. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), China Alliance for Rare Diseases, RDPAC, China Pharmaceutical Innovation and Research Development Association, China National Pharmaceutical Industry Information Center, domestic and international enterprises jointly announced the proposal of“Caring for Rare Disease Community and Achieving Social Harmony” during the 2022 China Conference on Rare Diseases held on 29 October 2022.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the “Most Valuable Companies in Hong Kong 2022 Awards” by Mediazone Group, an international business magazine publisher, in recognition of its extensive research and development experience and solid infrastructures. Please refer to the link below for a full media coverage by Mediazone Group. http://www.mediazone.com.hk/hkmvc/2022/11/08/revolutionizing-healthcare-through-innovative-drug-research-development/

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 26 October 2022, AU409, an investigational new drug candidate, drug product manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited (“Zhaoke Guangzhou”), a wholly-owned subsidiary of the Group, has been approved by the United States Food and Drug Administration (“US FDA”) to conduct clinical trial in patients with advanced primary liver cancers or advanced solid tumor with liver predominant metastatic disease in the United States.

Lee’s Pharm has collaborated with Lok Sin Tong Community Pharmacy to donate a total of 900 boxes of masks to support the community. Please contact Lok Sin Tong Community Pharmacy for more details.

Recently, the China National Intellectual Property Administration (CNIPA) announced the honours list of “2022 Excellent Enterprise and Role Model Enterprise of China National Intellectual Property”. Having strong innovative capabilities in research and development and well-established intellectual property management system, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was recognized as “2022 Excellent Enterprise of National Intellectual Property”, only one biopharmaceutical company in Anhui Province was awarded.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on September 20, 2022, the marketing authorization for generics of Azilsartan tablets (specification: 20mg), developed and manufactured by the Group, has been obtained from the China National Medical Products Administration (“NMPA”) (國藥准字H20223680). The drug has been approved to treat hypertension.

Hong Kong, September 3, 2022, “the Healthcare and Biotech Road Map in Greater Bay Area” Symposium, sponsored by Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), was successfully held both virtually and physically at the center of Hong Kong Management Association. Lee’s Pharm was awarded with the certificate issued by Greater Bay Area Medical Professional Study Group for its steadfast support and generosity.